Triumph Capital Management bought a new position in shares of BlackRock Capital Allocation Term Trust (NYSE:BCAT – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 43,443 shares of the company’s stock, valued at approximately $692,000.
A number of other institutional investors and hedge funds have also bought and sold shares of BCAT. Geneos Wealth Management Inc. lifted its position in BlackRock Capital Allocation Term Trust by 341.7% during the second quarter. Geneos Wealth Management Inc. now owns 2,045 shares of the company’s stock worth $31,000 after acquiring an additional 1,582 shares during the last quarter. McIlrath & Eck LLC grew its position in shares of BlackRock Capital Allocation Term Trust by 169.6% in the first quarter. McIlrath & Eck LLC now owns 3,130 shares of the company’s stock valued at $44,000 after purchasing an additional 1,969 shares during the last quarter. Parallel Advisors LLC acquired a new position in shares of BlackRock Capital Allocation Term Trust in the third quarter valued at approximately $47,000. Brown Brothers Harriman & Co. increased its stake in shares of BlackRock Capital Allocation Term Trust by 450.0% during the third quarter. Brown Brothers Harriman & Co. now owns 5,500 shares of the company’s stock worth $81,000 after purchasing an additional 4,500 shares during the period. Finally, Global Retirement Partners LLC bought a new position in shares of BlackRock Capital Allocation Term Trust during the second quarter worth approximately $115,000. Institutional investors and hedge funds own 36.12% of the company’s stock.
BlackRock Capital Allocation Term Trust Price Performance
NYSE:BCAT opened at $15.82 on Wednesday. The stock has a 50 day simple moving average of $15.81 and a 200 day simple moving average of $15.36. BlackRock Capital Allocation Term Trust has a 1-year low of $13.73 and a 1-year high of $16.20.
BlackRock Capital Allocation Term Trust Announces Dividend
BlackRock Capital Allocation Term Trust Profile
BlackRock Capital Allocation Term Trust (NYSE: BCAT) is a closed-end, diversified management investment company organized as a term trust. The fund’s primary objective is to deliver high current income and total return by investing across a broad range of credit and equity markets. BCAT seeks to achieve this objective through a portfolio of corporate debt securities, floating-rate loans, convertible securities, common and preferred equity, and asset-backed securities.
BCAT employs an actively managed, multi-sector credit approach that spans investment-grade and below-investment-grade bonds, senior secured loans and structured credit.
Read More
- Five stocks we like better than BlackRock Capital Allocation Term Trust
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Want to see what other hedge funds are holding BCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BlackRock Capital Allocation Term Trust (NYSE:BCAT – Free Report).
Receive News & Ratings for BlackRock Capital Allocation Term Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlackRock Capital Allocation Term Trust and related companies with MarketBeat.com's FREE daily email newsletter.
